Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VetoquinolVETOF 91 Owner Earnings per Share (TTM) is 8.39 as of Dec. 2025. GuruFocus rates VETOF with a GF Score™ of 91/100 and a GF Value™ of $95.03. The stock has 1 warning sign investors should review. Among 463 Drug Manufacturers companies, Vetoquinol ranks better than 76.46% on this metric.
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Vetoquinol does not have enough data to calculate Owner Earnings per Share (TTM), so as Price-to-Owner-Earnings ratio.
The historical rank and industry rank for Vetoquinol's Owner Earnings per Share (TTM) or its related term are showing as below:
VETOF'
s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.57 Med: 15.44 Max: 34.01
Current: 10.82
During the past 13 years, the highestPrice-to-Owner-Earnings ratio of Vetoquinol was 34.01. The lowest was 9.57. And the median was 15.44.
VETOF's Price-to-Owner-Earnings is ranked better than 76.46% of 463
companies
in the Drug Manufacturers industry
Industry Median: 22.27
vs VETOF: 10.82
Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.
Note: GuruFocus' Change In Working Capital is provided by FactSet. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.
Vetoquinol Owner Earnings per Share (TTM) Related Terms
Vetoquinol Owner Earnings per Share (TTM) Historical Data
* Premium members only.
The historical data trend for Vetoquinol's Owner Earnings per Share (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VETOF vs ZTS, UTHR, VTRS: Owner Earnings per Share (TTM) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vetoquinol's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vetoquinol Price-to-Owner-Earnings vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vetoquinol's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where Vetoquinol's Price-to-Owner-Earnings falls into.
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
What does a Owner Earnings per Share (TTM) of 8.39 mean?
Vetoquinol (VETOF) has a Owner Earnings per Share (TTM) of 8.39 as of Dec. 2025. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Vetoquinol. According to the industry distribution chart, Vetoquinol ranks #109 out of 463 companies in the Drug Manufacturers industry, placing it in the top 23.5%.
Is Vetoquinol's Owner Earnings per Share (TTM) too high?
Vetoquinol's current Owner Earnings per Share (TTM) is 8.39. The Drug Manufacturers industry median Owner Earnings per Share (TTM) is 22.27. Vetoquinol's value of 8.39 is 62.3% below this industry median. Based on the distribution chart, Vetoquinol ranks #109 out of 463 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vetoquinol has a GF Score™ of 91/100, reflecting its overall financial health beyond just this single metric.
How does Vetoquinol's Owner Earnings per Share (TTM) compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vetoquinol ranks #109 out of 463 companies for Owner Earnings per Share (TTM). This places Vetoquinol in the top 24% of its industry — outperforming the majority of peers. The industry median Owner Earnings per Share (TTM) is 22.27. Vetoquinol's value of 8.39 is 62.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Drug Manufacturers company?
The median Owner Earnings per Share (TTM) among Drug Manufacturers companies is 22.27, based on 463 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vetoquinol's current Owner Earnings per Share (TTM) of 8.39 is 62.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Vetoquinol. For the Drug Manufacturers industry, the median Owner Earnings per Share (TTM) is 22.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vetoquinol's current Owner Earnings per Share (TTM) is 8.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vetoquinol stock overvalued right now?
Vetoquinol (VETOF) has a current Owner Earnings per Share (TTM) of 8.39. The stock's GF Value™ is $95.03, compared to a current price of $90.80 — trading 4.5% below its estimated fair value. The current Owner Earnings per Share (TTM) is 8.39 and 62.3% below the Drug Manufacturers industry median of 22.27. Vetoquinol's overall GF Score™ is 91/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For Vetoquinol (VETOF), the current Owner Earnings per Share (TTM) is 8.39 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vetoquinol (VETOF) Overvalued in 2026?
Based on GuruFocus' analysis, Vetoquinol stock appears to be undervalued.
The current stock price of $90.80 is trading 4.5% below its estimated GF Value™ of $95.03.
Key valuation signals for VETOF:
Owner Earnings per Share (TTM): 8.39
GF Value™: $95.03 vs. price of $90.80 (4.5% below fair value)
Industry Position: 62.3% below the Drug Manufacturers median (#109 of 463)
No single metric tells the full story. See the VETOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vetoquinol SA operates is a France-based firm serving in the healthcare market. Its focus lies on developing and marketing veterinary drugs mainly in the European region and to a certain extent in America and Asia. Its portfolio of drugs entails anti-infectives, anti- pain inflammatory drugs, cardiovascular and nephrology treatment intended mainly for pets and livestock.
91GF Score
Get the complete analysis for VETOF
Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VETOF has been successfully added to your 
